Aducanumab is a Monoclonal Antibody owned by Biogen, and is involved in 7 clinical trials, of which 5 were completed, and 2 are ongoing.

Aducanumab (BIIB-037, NI-101, BART) inhibits beta-amyloid (amyloid precursor protein). Amyloid is a general term for protein fragments that the body produces normally. Beta amyloid is a protein fragment snipped from an amyloid precursor protein (APP). In a healthy brain, these protein fragments are broken down and eliminated. In Alzheimer's disease, the fragments accumulate to form hard, insoluble plaques.

The revenue for Aducanumab is expected to reach a total of $20m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Aducanumab NPV Report.

Aducanumab was originated by Neurimmune and is currently owned by Biogen.

Aducanumab Overview

Aducanumab (Aduhelm) is a recombinant human immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta, and is expressed in a Chinese hamster ovary cell line. It is formulated as injectable solution for intravenous and subcutaneous route of administration. Aduhelm is indicated for the treatment of Alzheimer’s disease.


Aducanumab (BIIB-037, NI-101, BART) is under development for the treatment of Alzheimer's disease (AD). The drug candidate is administered intravenously. The drug candidate is an anti-beta-amyloid (amyloid precursor protein) monoclonal antibody and is based on Reverse Translational Medicine (RTM) platform.

Biogen Overview

Biogen is a biopharmaceutical company that discovers, develops, and delivers drugs and biosimilars for the treatment of various neurological and neurodegenerative diseases. The company’s marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Fampyra (prolonged-release fampridine tablets), and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); and Fumaderm (fumaric acid esters) for severe plaque psoriasis. It has several product candidates targeting various indications such as MS, Parkinson’s disease, CNS and neuromuscular disorders, Alzheimer’s disease, and idiopathic pulmonary fibrosis and stroke. The company sells its products through direct sales force, marketing groups, and distributors in the Americas, Europe, Asia, and other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.

The company reported revenues of (US Dollars) US$10,981.7 million for the fiscal year ended December 2021 (FY2021), a decrease of 18.3% over FY2020. In FY2021, the company’s operating margin was 25.9%, compared to an operating margin of 33.8% in FY2020. In FY2021, the company recorded a net margin of 14.2%, compared to a net margin of 29.8% in FY2020. The company reported revenues of US$2,508.5 million for the third quarter ended September 2022, a decrease of 3.1% over the previous quarter.

Quick View – Aducanumab

Report Segments
  • Innovator (NME)
Drug Name
  • Aducanumab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.